Equillium (EQ) Stock News

Equillium (Nasdaq: EQ) presented research findings at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, highlighting the synergistic effects of IL-15 and IL-21 on immune cell responses. The research demonstrated that these cytokines together enhance NK and CD8+ T cell activity, boost cytolytic function, and partially rescue exhausted T cells. The study showed increased production of granzyme A, granzyme B and perforin, indicating important roles in immune cell activation and survival. Dr. Stephen Connelly, chief scientific officer, emphasized the importance of targeting both cytokines in a single agent for treating inflammatory diseases or enhancing anti-tumor responses.

Equillium announced that Ono Pharmaceutical has allowed its option to acquire rights to itolizumab to expire, with Equillium maintaining all commercial rights. The decision was strategic and unrelated to clinical data. Equillium is evaluating accelerating completion of the Phase 3 EQUATOR study in aGVHD to Q1 2025. The company has enrolled over 150 patients and is temporarily pausing enrollment to review clinical options. A Phase 2 ulcerative colitis study was recently completed with topline data expected in Q1 2025. The company believes it has sufficient cash to achieve these milestones and extend operations into Q4 2025.

Equillium announced that an abstract was accepted for a poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer.

The conference will be held from November 6 to 10, 2024, at the George R. Brown Convention Center in Houston, Texas. The abstract, titled Interleukin (IL)-15 and IL-21 synergistically enhance NK and CD8+ T cell responses, will be presented by Phoi Tiet, Senior Research Associate at Equillium, on November 9, 2024.

The abstract highlights the potential of IL-15 and IL-21 to augment NK and CD8 T cell activities, enhancing their proliferation and cytolytic function. This combination could be a promising approach to stimulating anti-tumor immune responses.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, has announced its participation in the Stifel Virtual Inflammation & Immunology Summit on September 17 & 18. The company will present on Tuesday, September 17, at 1:00 pm PT / 4:00 pm ET, providing an overview of its:

• Multi-cytokine inhibitor programs and platform
• Focus on dermatological and gastrointestinal indications
• Ongoing development of itolizumab in partnership with Ono Pharmaceutical
• Ono's pending option exercise decision to potentially acquire Equillium's rights to itolizumab

Management will be available for one-on-one meetings during the conference. A webcast of the presentation will be accessible on the company's website, with an archived replay available for 90 days.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics for severe autoimmune and inflammatory disorders, has announced an inducement grant to a new employee. The Compensation Committee of Equillium's Board of Directors granted a nonstatutory stock option to purchase 10,000 shares of common stock under the company's 2024 Inducement Plan on August 30, 2024.

The stock option has an exercise price of $1.07 per share, equal to Equillium's closing stock price on the grant date. It will vest over four years, with 25% vesting on the one-year anniversary and the remaining balance vesting monthly over 36 months, subject to the employee's continued service. This grant was approved in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to the new employee's employment.

Equillium (Nasdaq: EQ), a clinical-stage biotech company, announced its participation in two major healthcare conferences: the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference. At these events, Equillium's management will present an overview of their multi-cytokine inhibitor programs and platform, focusing on dermatological and gastrointestinal indications. They will also discuss the ongoing development of itolizumab in partnership with Ono Pharmaceutical.

The Wells Fargo conference presentation is scheduled for September 5 at 4:30 pm ET, while the H.C. Wainwright conference presentation will take place on September 10 at 8:00 am ET. Both presentations will be available via webcast on Equillium's website, with replays accessible for 90 days. The company will also be available for one-on-one meetings during both conferences.

Equillium Inc. (Nasdaq: EQ) reported Q2 2024 financial results and provided corporate updates. Key highlights include:

- Cash balance of $33.3 million at Q2 end, up $1.0 million from Q1
- Revenue of $13.9 million, compared to $9.1 million in Q2 2023
- Net income of $0.5 million, or $0.01 per share, vs. net loss of $3.3 million in Q2 2023
- Positive interim analysis of Phase 3 EQUATOR study for itolizumab in acute graft-versus-host disease
- Positive topline data from Phase 1b EQUALISE study in lupus nephritis and Phase 2 study of EQ101 in alopecia areata

Ono Pharmaceutical's option exercise period for itolizumab rights was triggered, with a decision expected by October 2024. If exercised, Equillium would receive approximately $35 million upfront and be eligible for up to $101.4 million in milestone payments.

Equillium (Nasdaq: EQ) announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) for its Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). The IDMC reviewed unblinded data from over 100 patients through Day 29 of treatment and recommended the study continue without modifications. This outcome triggers a 90-day period for Ono Pharmaceutical to exercise its option to acquire Equillium's rights to itolizumab for JPY 5 billion (approximately $35 million) plus potential milestone payments of up to $101.4 million. Equillium CEO Bruce Steel expressed optimism about itolizumab's potential benefit for aGVHD patients, where mortality rates are high and first-line treatment remains high-dose corticosteroids.

Equillium Inc (Nasdaq: EQ), a clinical-stage biotech company, has announced its estimated Q2 2024 financial position. The company's cash, cash equivalents, and short-term investments totaled approximately $33.3 million at the end of Q2, marking an increase of about $1.0 million from Q1 2024. This increase is primarily attributed to a $2.7 million tax credit received from the Australian tax authority for 2023 R&D expenses.

Equillium plans to release its complete Q2 2024 financial results around August 8. The company emphasizes that these figures are preliminary and subject to final adjustments. The data has not been audited or reviewed by an independent accounting firm and should not be considered a substitute for official financial statements.